Comparability of Drug Substance and Drug Product manufactured at 2,000L scale achievedMedia Release SYDNEY, AUSTRALIA, Sept. 21, 2023 (GLOBE NEWSWIRE)...
Receives first purchase order from Gensco® PharmaSAINT LAURENT, Quebec, Sept. 21, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company"...
AFFIRM is a unique event-driven, fixed-duration design intended to reduce the challenges for patient participation Data will be used to...
TORONTO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...
All three Fanconi Anemia patients treated with briquilimab achieved full donor engraftment and full blood count recoveryBriquilimab was well tolerated...
SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today...
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis,...
SOUTH SAN FRANCISCO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that senior management will...
- 850 cancer cell lines screened in Broad Institute’s PRISM lab - - Rencofilstat active on 220 cancer cell lines...
BOSTON and LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a late-stage...
Southlake, TX, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the...
TORONTO, Ontario and ALGOMA, Ontario and DRYDEN, Ontario and THUNDER BAY, Ontario, Sept. 21, 2023 (GLOBE NEWSWIRE) -- The people...
SAN MATEO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc. a private clinical stage biopharmaceutical company focused on...
Successful Audit of the Company’s State-of-the-Art Manufacturing Facility Represents a Key Milestone Toward Plan to Commercialize D-PLEX₁₀₀ GloballyPETACH TIKVA, Israel,...
MALVERN, Pa., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused...
- Phase 2a NASH protocol on track to be submitted to the IND in Q4 2023, enrollment expected to begin...
SIKLOS® (hydroxyurea) is now covered by State Medicaid programs in 19 states Medunik USA (member of Duchesnay Pharmaceutical Group) is...
- New data from multi-dose GLP toxicology study of SNS-101 in cynomolgus monkeys further support exceptional PK and safety profile...
FILSPARI® (sparsentan) achieved a clinically meaningful difference vs. irbesartan in eGFR total slope (1.0 mL/min/1.73m2 per year) and eGFR chronic...
Company’s First-Ever ANPT Booth Sponsorship Enables Specialists to Learn More about this Breakthrough Technology on Eve of National Physical Therapy...